Sagimet Biosciences (STU:0O2) FCF Yield %: -9.11 (As of Jun. 28, 2026)


STU:0O2 Sagimet Biosciences Inc STU:0O2
10 GF Score
Price €6.14
! 2 Warning Signs
View Full Analysis

What is Sagimet Biosciences FCF Yield %?

Sagimet Biosciences STU:0O2 +1.66% 10 FCF Yield % is -9.11 as of Jun. 28, 2026. GuruFocus rates STU:0O2 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, Sagimet Biosciences ranks better than 51.06% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Sagimet Biosciences's Trailing 12-Month Free Cash Flow is €-34.12 Mil, and Market Cap is €383.73 Mil. Therefore, Sagimet Biosciences's FCF Yield % for today is -9.11%.

The historical rank and industry rank for Sagimet Biosciences's FCF Yield % or its related term are showing as below:

STU:0O2' s FCF Yield % Range Over the Past 10 Years
Min: -51.32   Med: -14.84   Max: -6.98
Current: -9.11


During the past 7 years, the highest FCF Yield % of Sagimet Biosciences was -6.98%. The lowest was -51.32%. And the median was -14.84%.

STU:0O2's FCF Yield % is ranked better than
51.06% of 1416 companies
in the Biotechnology industry
Industry Median: -9.62 vs STU:0O2: -9.11

Sagimet Biosciences's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.


Sagimet Biosciences FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Sagimet Biosciences FCF Yield % Related Terms


Sagimet Biosciences FCF Yield % Historical Data

* Premium members only.

The historical data trend for Sagimet Biosciences's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sagimet Biosciences FCF Yield % Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial 0.00 0.00 -18.30 -27.13 -24.27

Sagimet Biosciences Quarterly Data
Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -54.95 -15.20 -18.39 -25.16 -20.41

STU:0O2 vs NGNE, UPB, STTK: FCF Yield % Comparison

For the Biotechnology subindustry, Sagimet Biosciences's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sagimet Biosciences FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Sagimet Biosciences's FCF Yield % falls into.


STU:0O2
10GF Score
Sagimet Biosciences Inc STU:0O2
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sagimet Biosciences FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Sagimet Biosciences's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-38.985 / 160.65868
=-24.27%

Sagimet Biosciences's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-7.449 * 4 / 145.9808
=-20.41%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -9.11 mean?
Sagimet Biosciences (STU:0O2) has a FCF Yield % of -9.11 as of Jun. 28, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Sagimet Biosciences and its competitors. According to the industry distribution chart, Sagimet Biosciences ranks #693 out of 1416 companies in the Biotechnology industry, placing it in the top 48.9%.
Is Sagimet Biosciences' FCF Yield % too high?
Sagimet Biosciences' current FCF Yield % is -9.11. Based on the distribution chart, Sagimet Biosciences ranks #693 out of 1416 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' FCF Yield % compare to NGNE and UPB?
According to the Biotechnology industry distribution chart, Sagimet Biosciences ranks #693 out of 1416 companies for FCF Yield %. This puts Sagimet Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Sagimet Biosciences and its competitors. Sagimet Biosciences's current FCF Yield % is -9.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current FCF Yield % of -9.11. The current FCF Yield % is -9.11. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current FCF Yield % is -9.11 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sagimet Biosciences Business Description

Other Exchanges SGMT:USA
Address 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score

Get the complete analysis for STU:0O2

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.14
Price